BioPharma Resources

Drug Trial Radar · NCT04304040

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

A Phase I/IIa Study on Dose-escalation and Extension of Recombinant Humanized Type II CD20 Monoclonal Antibody MIL62 Injection Combined With BTK Inhibitor Orelabrutinib in the Treatment of Recurrent/Refractory CD20+B-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

43

Actual

Start

Jul 28, 2020

Primary completion

Dec 30, 2025

Study completion Dec 30, 2025

Sponsor

Sponsor type
Industry
First posted
Mar 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma

Conditions

  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory

Interventions

  • OrelabrutinibDrug

    BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

  • Recombinant humanized monoclonal antibody MIL62 injectionDrug

    Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)(Dose escalation phase)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Maximum tolerated dose (MTD) (Dose escalation phase)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Recommended dose for phase 2 trials of two-drug combinations (RP2D) (Dose escalation phase)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  4. objective remission rate(ORR) (Dose expansion phase)Time frame: At the end of Cycle 30 (each cycle is 28 days)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Beijing Shijitan hospital, capital medical university

    Beijing, Beijing Municipality, China

  • Cancer hospital, Chinese academy of medical sciences

    Beijing, Beijing Municipality, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Henan Tumor Hospital

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • Tianjin People's Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.